| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | clonazepam |
| Formulation | 0.5 mg/5 ml and 2 mg/5 ml oral solution |
| Reference number | 1679 |
| Indication | Treatment of all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements |
| Company | Rosemont Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 23/05/2013 |